Patents by Inventor Kevin J. Tracey

Kevin J. Tracey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030143194
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including, septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: November 20, 2002
    Publication date: July 31, 2003
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20030144201
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Application
    Filed: November 20, 2002
    Publication date: July 31, 2003
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink
  • Publication number: 20030113323
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: September 11, 2002
    Publication date: June 19, 2003
    Applicant: North Shore - Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20030060410
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMG A box, and an antibody preparation that specifically binds to a vertebrate HMG B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Application
    Filed: May 15, 2002
    Publication date: March 27, 2003
    Applicant: North Shore Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink
  • Publication number: 20030017155
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: July 31, 2002
    Publication date: January 23, 2003
    Applicant: North Shore-Long island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20020193412
    Abstract: There is disclosed a genus of compounds and pharmaceutical compositions that are protective for mitigating damage associated with tissue ischemia, particularly stroke (CNS ischemia), and ischemia of the myocardium. The present invention further provides a method for treating tissue damage caused by ischemia. Lastly, the present invention provides a method for treating tissue damage caused by providing a compound that inhibits the cytotoxic activity of 3-aminopropanal.
    Type: Application
    Filed: May 7, 2002
    Publication date: December 19, 2002
    Inventors: Kevin J. Tracey, Yousef Al-Abed, Svetlana Ivanova, Richard J. Bucala
  • Patent number: 6482833
    Abstract: There is disclosed a class of pharmaceutical compositions useful for the treatment of cancer, particularly solid tumors, and having a mechanism of action as spermine antagonists. The present pharmaceutical compositions are able to inhibit the inhibitory effect of spermine upon macrophage function, and thus prevent spermine-induced immunosuppression.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: November 19, 2002
    Assignee: North Shore - Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Minghuang Zhang
  • Patent number: 6468533
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: October 22, 2002
    Assignee: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Patent number: 6448223
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: September 10, 2002
    Assignee: North Shore - Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20020122821
    Abstract: There is disclosed a class of pharmaceutical compositions useful for the treatment of cancer, particularly solid tumors, and having a mechanism of action as spermine antagonists. The present pharmaceutical compositions are able to inhibit the inhibitory effect of spermine upon macrophage function, and thus prevent spermine-induced immunosuppression.
    Type: Application
    Filed: January 18, 2000
    Publication date: September 5, 2002
    Inventors: Kevin J. Tracey, Minghuang Zhang
  • Publication number: 20020102609
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: August 15, 2001
    Publication date: August 1, 2002
    Applicant: North Shore - Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Patent number: 6391899
    Abstract: There is disclosed a genus of compounds and pharmaceutical compositions that are protective for mitigating damage associated with tissue ischemia, particularly stroke (CNS ischemia), and ischemia of the myocardium. The present invention further provides a method for treating tissue damage caused by ischemia. Lastly, the present invention provides a method for treating tissue damage caused by providing a compound that inhibits the cytotoxic activity of 3-aminopropanal.
    Type: Grant
    Filed: July 17, 1998
    Date of Patent: May 21, 2002
    Assignee: North Shore—Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Yousef Al-Abed, Svetlana Ivanova, Richard J. Bucala
  • Publication number: 20020028851
    Abstract: This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.
    Type: Application
    Filed: April 3, 2001
    Publication date: March 7, 2002
    Inventors: Marina Bianchi, Anthony Cerami, Kevin J. Tracey, Peter Ulrich
  • Publication number: 20020016344
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Application
    Filed: May 15, 2001
    Publication date: February 7, 2002
    Inventor: Kevin J. Tracey
  • Patent number: 6303321
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including, septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: October 16, 2001
    Assignee: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Patent number: 6248356
    Abstract: There is disclosed a class of pharmaceutical compositions useful for the treatment of cancer, particularly solid tumors, and having a mechanism of action as spermine antagonists. The present pharmaceutical compositions are able to inhibit the inhibitory effect of spermine upon macrophage function, and thus prevent spermine-induced immunosuppression.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: June 19, 2001
    Assignee: The Picower Institut for Medical Research
    Inventors: Kevin J. Tracey, Minghuang Zhang
  • Patent number: 6248787
    Abstract: This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 19, 2001
    Assignee: The Picower Institute for Medical Research
    Inventors: Marina Bianchi, Anthony Cerami, Kevin J. Tracey, Peter Ulrich
  • Patent number: 6180676
    Abstract: This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 30, 2001
    Assignee: The Picower Institute for Medical Research
    Inventors: Marina Bianchi, Anthony Cerami, Kevin J. Tracey, Peter Ulrich
  • Patent number: 6143728
    Abstract: There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection, using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: November 7, 2000
    Assignee: The Picower Institute for Medical Research
    Inventors: Kevin J. Tracey, Pamela Cohen, Michael Bukrinsky, Helena Schmidtmayerova
  • Patent number: 6117837
    Abstract: There is disclosed a method for helping to prevent miscarriages during pregnancy, comprising administering an effective amount of a fetuin polypeptide.
    Type: Grant
    Filed: January 4, 2000
    Date of Patent: September 12, 2000
    Assignee: The Picower Institute for Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang